Yasuhiro Shirakawa

Risk factors for recurrence after neoadjuvant docetaxel+cisplatin+5-fluorouracil (DCF) followed by surgery for esophageal squamous cell carcinoma: a single-institution retrospective analysis

The JCOG1109 trial proved the superiority of neoadjuvant chemotherapy (NAC) with docetaxel, cisplatin, and 5-fluorouracil (DCF) to chemotherapy with cisplatin and 5-fluorouracil (CF). Concurrently, advances in immune checkpoint inhibitors (ICIs) have introduced new perioperative...